45 Gray (Gy) regimen for Non-small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Non-small Cell Lung Cancer45 Gray (Gy) regimen - Radiation
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a lower-dose SBRT regimen for tumors in the chest.

Eligible Conditions
  • Non-small Cell Lung Cancer

Treatment Effectiveness

Study Objectives

2 Primary · 5 Secondary · Reporting Duration: Up to 10 years post-enrollment.

Year 2
Safety of the stereotactic body radiotherapy regimen (SBRT)
Year 10
distant control
lobar control
local control (LC) of 3-fraction stereotactic body radiotherapy
organ at risk (OAR) dosimetry
overall survival
progression-free survival
regional control
Year 5
quality of life (QOL)

Trial Safety

Trial Design

1 Treatment Group

45 Gy
1 of 1

Experimental Treatment

60 Total Participants · 1 Treatment Group

Primary Treatment: 45 Gray (Gy) regimen · No Placebo Group · Phase 1 & 2

45 Gy
Radiation
Experimental Group · 1 Intervention: 45 Gray (Gy) regimen · Intervention Types: Radiation

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 10 years post-enrollment.

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,680 Previous Clinical Trials
21,088,199 Total Patients Enrolled
3 Trials studying Non-small Cell Lung Cancer
171 Patients Enrolled for Non-small Cell Lung Cancer
Henry S. Park, MD, MPHPrincipal InvestigatorYale University

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: